1. The Cliff Everyone Sees Coming — and Still Falls Off Every branded pharmaceutical product carries a date of death. […]

An investigative analysis of patent thickets, design-around strategies, and competitive intelligence for pharmaceutical generics manufacturers The Wall Every Generic Manufacturer

A country-by-country guide for pharmaceutical executives, generic manufacturers, and IP professionals operating across 54 markets The Patent Map Nobody Prints

How to conduct a freedom-to-operate analysis that holds up in court, survives investor due diligence, and actually protects your pipeline

An Investigative Analysis of Pharmaceutical and Biotech Valuation Frameworks Why Most Biotech Valuations Get It Wrong Every quarter, analysts revise

What You Actually Need to Know About the Dual Shield Most people conflate drug patents with drug exclusivity. They are

How generic drug companies legally exploit the Hatch-Waxman framework to generate billion-dollar windfalls — and how brand manufacturers fight back

The Patent Clock Nobody Shows You The standard answer to “how long does a patent last?” is 20 years. You

How payers, PBMs, and formulary committees can convert LOE intelligence into measurable cost savings — and why most of them